EU/3/17/1971

Table of contents

About

On 17 January 2018, orphan designation (EU/3/17/1971) was granted by the European Commission to Edison Orphan Pharma BV, The Netherlands, for vatiquinone (also known as alpha-tocotrienol quinone) for the treatment of RARS2 syndrome.

Key facts

Active substance
Vatiquinone
Disease / condition
Treatment of RARS2 syndrome
Date of decision
17/01/2018
Outcome
Positive
Orphan decision number
EU/3/17/1971

Sponsor's contact details

Edison Orphan Pharma BV
Marconistraat 16
Room 9.01
Rotterdam
3029 AK
The Netherlands
Tel. + 31 6204 43098
E-mail: info@bioelectron.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating